Aclaris Therapeutics, Inc.
ACRS
$1.34
-$0.15-10.07%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -47.58% | -53.18% | 47.99% | -5.14% | 131.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -47.58% | -53.18% | 47.99% | -5.14% | 126.62% |
| Cost of Revenue | -56.44% | -68.64% | -60.29% | -52.22% | 313.64% |
| Gross Profit | 58.49% | 141.07% | 68.39% | 57.65% | -411.39% |
| SG&A Expenses | -32.27% | -20.28% | -42.86% | -22.14% | 2.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.01% | -64.20% | -56.17% | -44.27% | 28.38% |
| Operating Income | 31.70% | 67.63% | 62.02% | 47.49% | 6.28% |
| Income Before Tax | -5,096.56% | 74.07% | 62.85% | 39.84% | 93.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6,375.65% | 74.07% | 62.85% | 39.84% | 94.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6,375.65% | 74.07% | 62.85% | 39.84% | 94.60% |
| EBIT | 31.70% | 67.63% | 62.02% | 47.49% | 6.28% |
| EBITDA | 31.48% | 67.77% | 62.01% | 47.61% | -- |
| EPS Basic | -4,724.29% | 74.27% | 63.19% | 43.39% | 94.93% |
| Normalized Basic EPS | 55.79% | 75.59% | 65.59% | 54.08% | 15.64% |
| EPS Diluted | -4,216.17% | 74.27% | 63.19% | 43.39% | 94.33% |
| Normalized Diluted EPS | 55.79% | 75.59% | 65.59% | 54.08% | 15.64% |
| Average Basic Shares Outstanding | 34.49% | 0.81% | 0.93% | 6.28% | 6.27% |
| Average Diluted Shares Outstanding | 34.49% | 0.81% | 0.93% | 6.28% | 6.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
